SLC5A2 and Hypoglycemia: Currently, two pharmacologic classes, DPP4 inhibitors and SGLT2 inhibitors, show promise as preferred second-line treatment options given their weight neutral and weight lowering effects, respectively, and low potential for hypoglycemia.